Best of ESMO 2017 Congress
(European Society for Medical Oncology) ESMO 2017 was a truly global event with nearly 24,000 participants from 131 countries. The ten countries with the most delegates were the USA, France, Spain, UK, Germany, Italy, Switzerland, China, Japan, and Russia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 12, 2017 Category: Cancer & Oncology Source Type: news

Aluminum salts in deodorants caused CANCER, and Switzerland may be the first nation in the world to BAN them
(Natural News) Switzerland is slated to become the first country to ban deodorants that contain aluminum salts. This, following results of a 2016 study indicating that the toxic chemicals may play a role in breast cancer onset. The country’s National Council voted 126 to 58 in favor of approving a bill instructing the Federal Council to consider... (Source: NaturalNews.com)
Source: NaturalNews.com - September 11, 2017 Category: Consumer Health News Source Type: news

Roche shares hit by trial flops, fears over biosimilar defense
ZURICH (Reuters) - Roche shares fell in early trading on Monday after trial failures added to the Swiss drugmaker's challenge of replacing patent-expired medicines with lucrative new drugs. (Source: Reuters: Health)
Source: Reuters: Health - September 11, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

The 2017 Balzan Prizewinners announced today in Milan
(Gold Communications) The names of the 2017 Balzan Prizewinners were disclosed today in a public announcement: 750,000 Swiss Francs (approx. € 660,000; $790,000) for each of the subjects. Half of the amount must be destined by the winners to research projects. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 11, 2017 Category: International Medicine & Public Health Source Type: news

Novartis posts a win, Roche a flop in skin cancer trials
ZURICH/MADRID (Reuters) - Swiss drugmaker Novartis notched a trial win for its drug cocktail against skin cancer on Monday, while a rival treatment from Roche with slipping sales failed in a separate study with a similar patient group. (Source: Reuters: Health)
Source: Reuters: Health - September 10, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

PSI CRO growing abroad – and in Durham
The Triangle is a hotbed of contract research organizations, and Switzerland-based PSI CRO, which opened a Durham office in April of last year, is continuing to expand its presence abroad and locally. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - September 8, 2017 Category: American Health Authors: Jennifer Henderson Source Type: news

PSI CRO growing abroad – and in Durham
The Triangle is a hotbed of contract research organizations, and Switzerland-based PSI CRO, which opened a Durham office in April of last year, is continuing to expand its presence abroad and locally. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 8, 2017 Category: Biotechnology Authors: Jennifer Henderson Source Type: news

7 medtech stories we missed this week: Sept. 8, 2017
[Image from unsplash.com]From BrainScope’s pediatric traumatic brain injury assessment device to EOS Imaging releasing new surgery planning software, here are seven medtech stories we missed this week but thought were still worth a mention. 1. BrainScope to develop pediatric traumatic brain injury assessment device BrainScope announced in a Sept. 7 press release that it will immediately start creating a pediatric capability for its BrainScope One medical neurotechnology. The technology is an FDA-cleared handheld medical device that is designed to assess the full spectrum of traumatic brain injury. The company sa...
Source: Mass Device - September 8, 2017 Category: Medical Devices Authors: Danielle Kirsh Tags: 510(k) Cardiac Assist Devices Cardiovascular Clinical Trials Diagnostics Food & Drug Administration (FDA) Imaging mHealth (Mobile Health) Neurological Regulatory/Compliance Research & Development Spinal AliveCor Bonesupport Bra Source Type: news

Deals this week: Mundipharma Medical Company, Cooper Pharmal Sarl, Merck
Mundipharma Medical Company will exclusively distribute INVOKANA (canagliflozin) and VOKANAMET (canagliflozin and metformin) in the European Economic Area (EEA) and Switzerland, under an agreement signed with drug developer and manufacturer Janssen P … (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - September 7, 2017 Category: Pharmaceuticals Source Type: news

Researchers break through the wall in bacterial membrane vesicle research
(University of Tsukuba) Japanese and Swiss researchers used advanced imaging techniques to investigate the formation of membrane vesicles in a Gram-positive bacterium, a process that is poorly understood, particularly in bacteria with thick cell walls. The consortium showed that membrane vesicle formation was triggered by an enzyme called endolysin that damages the cell wall to create holes that allow the release of membrane vesicles. This mechanism could be exploited for the mass production of bacterial vesicles. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - September 7, 2017 Category: Biology Source Type: news

NAS, NAM Members Receive Lasker Awards
The Albert and Mary Lasker Foundation announced today that NAS member Michael N. Hall, professor, Biozentrum, University of Basel, Switzerland, is the recipient of the 2017 Albert Lasker Basic Medical Research Award for"discoveries concerning the nutrient-activated TOR proteins and their central role in the metabolic control of cell growth." Dual NAS/NAM member Douglas Lowy, acting director of the National Cancer Institute, has been awarded the 2017 Lasker~DeBakey Clinical Medical Research Award, along with John T. Schiller of the NCI, for"technological advances that enabled development of HPV vaccines for p...
Source: News from the National Academies - September 6, 2017 Category: Science Source Type: news

3 Scientists and Planned Parenthood Win Lasker Prizes for Medical Research
(NEW YORK) — Two scientists who paved the way for widely used vaccines and another who discovered key players in cell growth have been awarded prestigious medical research awards. The Albert and Mary Lasker Foundation also announced Wednesday that it was giving its public service award to Planned Parenthood. Each award includes a $250,000 honorarium. The foundation’s clinical research award is shared by Dr. Douglas Lowy and John Schiller of the U.S. National Cancer Institute. In the early 1990s they began work that would eventually lead to vaccines against human papillomavirus, or HPV, which causes cervical can...
Source: TIME.com: Top Science and Health Stories - September 6, 2017 Category: Consumer Health News Authors: Malcolm Ritter / AP Tags: Uncategorized awards medical research onetime Planned Parenthood Science Source Type: news

Kapanu 3D gives patients virtual view of expected health
Kapanu 3D, created by Swiss researchers, allows adults seeking a Hollywood smile to choose their desired smile right in front of their eyes - based on current scans of their mouth. (Source: the Mail online | Health)
Source: the Mail online | Health - September 6, 2017 Category: Consumer Health News Source Type: news

Nigeria: Experts Fault Proposed Field Trial of Genetically Modified Cassava
[Guardian] Abuja -Experts have condemned an alleged move by the International Institute of Tropical Agriculture, (IITA) and Zurich, Switzerland-based ETHZ Laboratories to carry out confined field trial of genetically modified cassava in Nigeria. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - September 6, 2017 Category: African Health Source Type: news

The bacteria responsible for legionellosis modulates the host cell metabolism to its advantage
(Institut Pasteur) Scientists at the Institut Pasteur, CNRS and Inserm, together with a team from Switzerland, have shown that the bacterial pathogen Legionella pneumophila has developed a specific strategy to target the host cell mitochondria, the organelles in charge of cellular bioenergetics. This work provides precious information on how a pathogen manipulates the cellular metabolism to replicate intracellularly, and proposes a new concept of protection of host cells from Legionella-induced mitochondrial changes in order to fight infection. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 6, 2017 Category: International Medicine & Public Health Source Type: news

EMBO at Basel Life, a new conference on current and emerging life science research
(EMBO) EMBO and Basel Life are pleased to announce the EMBO at Basel Life conference, taking place at the Congress Center Basel, Switzerland, from Sept. 10-13, 2017. A committee of leading scientists has organized this international and broad-scope scientific conference on current and emerging life science research to be held as part of Basel Life. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - September 6, 2017 Category: Biology Source Type: news

FDA grants rare paediatric disease designation for Novimmune ’s HLH emapalumab treatment
Swiss biopharmaceutical company Novimmune has received rare paediatric disease designation for its lead drug emapalumab from the US Food and Drug Administration (FDA) to treat patients with primary haemophagocytic lymphohistiocytosis (HLH). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - September 5, 2017 Category: Pharmaceuticals Source Type: news

Novartis Names Drugs Chief as CEO to Deliver Return to Growth Novartis Names Drugs Chief as CEO to Deliver Return to Growth
Novartis CEO Joe Jimenez will step down on Feb. 1 and hand over to drug development chief Vas Narasimhan to decide the fate of $50 billion in assets and make good on a pledge to return the Swiss company to sales growth.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 5, 2017 Category: Consumer Health News Tags: Pharmacist News Source Type: news

Novartis names chief to replace Jimenez who is to step down
Swiss group’s head of drug development Vas Narasimhan succeeds long-serving boss (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - September 4, 2017 Category: Pharmaceuticals Source Type: news

Novartis names drugs chief as CEO to deliver return to growth
ZURICH (Reuters) - Novartis CEO Joe Jimenez will step down on Feb. 1 and hand over to drug development chief Vas Narasimhan to decide the fate of $50 billion in assets and make good on a pledge to return the Swiss company to sales growth. (Source: Reuters: Health)
Source: Reuters: Health - September 4, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Africa: Zimbabwe to Chair 2018 World Health Assembly
[The Herald] Zimbabwe has been elected to chair the 71st World Health Assembly scheduled to take place between 21 and 26 May 2018 in Geneva, Switzerland. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - September 4, 2017 Category: African Health Source Type: news

Novartis's Jimenez stepping down, Narasimhan named new CEO
ZURICH (Reuters) - Novartis Chief Executive Joseph Jimenez will retire in 2018, with chief drug developer Vasant Narasimhan taking over as CEO starting in February, the Swiss drugmaker said on Monday. (Source: Reuters: Health)
Source: Reuters: Health - September 4, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Roche Diagnostics India looks at 15 per cent IVD market share in 2 years
Roche Diagnostics is part of Swiss healthcare major Roche. It sells devices and equipment to labs and hospitals and is mainly present in the business-to-business space. (Source: The Economic Times)
Source: The Economic Times - September 3, 2017 Category: Consumer Health News Source Type: news

Profit on $475,000 Novartis Cancer Drug Could Be a While Coming Profit on $475,000 Novartis Cancer Drug Could Be a While Coming
Novartis's new gene-modifying cancer therapy's $475,000-per-patient sticker price has drawn fire from advocate groups calling for cheaper drugs, but analysts said the Swiss drugmaker could initially struggle to break even.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 1, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Legal cannabis oil has Scott Disick and Snoop Dogg as fans
EXCLUSIVE SwissX is produced in the Swiss alps due to the growth of organic cannabidiol-rich plants. Unlike cannabis, SwissX does not contain the compound that causes people to hallucinate. (Source: the Mail online | Health)
Source: the Mail online | Health - September 1, 2017 Category: Consumer Health News Source Type: news

Profit on $475,000 Novartis cancer drug could be a while coming
ZURICH (Reuters) - Novartis's new gene-modifying cancer therapy's $475,000-per-patient sticker price has drawn fire from advocate groups calling for cheaper drugs, but analysts said the Swiss drugmaker could initially struggle to break even. (Source: Reuters: Health)
Source: Reuters: Health - August 31, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Nestle shuts Swiss skin health products factory
ZURICH (Reuters) - Nestle said on Thursday it was closing a Swiss factory which makes products for its skin health business, responding to a slowdown in a business once seen as one of its rising stars. (Source: Reuters: Health)
Source: Reuters: Health - August 31, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Swiss cheese found to contain powerful probiotic that promotes longevity
(Natural News) Researchers have found that cheese can now be considered a superfood – as long as it’s Swiss cheese. The bacterium Propionibacterium freudenreichii, which is used in the fermentation of Emmentaler – the proper name of Swiss cheese, because it came from the Emmental region of Switzerland – is found to be beneficial to... (Source: NaturalNews.com)
Source: NaturalNews.com - August 30, 2017 Category: Consumer Health News Source Type: news

FDA OKs first-of-its-kind T-cell cancer therapy developed by Penn & CHOP
The Food and Drug Administration approved a personalized cellular therapy treatment for leukemia developed by researchers at the University of Pennsylvania and Children ’s Hospital of Philadelphia. The T-Cell therapy, which will be marketed by Novartis as Kymriah, was OK'd as treatment for patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia that is refractory, or in second or later relapse. In 2012, Penn and Novartis — a Swiss dr ug company that has its U.S headquarters… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - August 30, 2017 Category: American Health Authors: John George Source Type: news

Breast cancer biosimilar approval delayed as US FDA reviews additional information by Biocon, Mylan
Biocon and Mylan have together developed the trastuzumab biosimilar, which is a copy of a complex biologic drug developed by Swiss biotech giant Roche. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - August 30, 2017 Category: Pharmaceuticals Source Type: news

Anti-inflammatory drug may help prevent heart attacks
Conclusion This well-conducted study shows promising signs that canakinumab may reduce the risk of future heart attacks and other cardiovascular events in people who've had them in the past. But before any changes are made to the current licensing of this drug, further research is needed to confirm the beneficial effects and the optimal dose. Most importantly, researchers will need to focus on the observation that the drug lowered white blood cell counts and increased the risk of fatal infection. They estimated around 1 in every 300 people taking canakinumab would die of a fatal infection. This number, while low, is sti...
Source: NHS News Feed - August 30, 2017 Category: Consumer Health News Tags: Heart/lungs Source Type: news

Open borders key to Swiss pharma’s EU success
Roche and Novartis could serve as models for UK drugmakers after Brexit (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - August 30, 2017 Category: Pharmaceuticals Source Type: news

Epidemiological trends in the Swiss rehabilitation setting for traumatic spinal cord injury (Safety-2016 abstract #308) - Chamberlain J, Brinkhof MWG.
BACKGROUND Dynamics of incident traumatic accidents, a case in point being traumatic spinal cord injury (TSCI), have changed over the past forty years in many high income countries due to changes in demographic structure, lifestyle and policy. Rehabilitati... (Source: SafetyLit)
Source: SafetyLit - August 29, 2017 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

Obese people lack cells with satiety hormones
This report by Swiss doctors is in the journal Scientific Reports. Surgical weight-loss procedures can repair this disorder. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - August 29, 2017 Category: Biology Source Type: news

​Head of Biogen's copycat drug unit leaves to join Scangos startup
The head of a Biogen division that makes biosimilars — cheaper, knockoff versions of popular biologic drugs — has left the Cambridge firm to become the chief operating officer of a startup led by former Biogen CEO George Scangos. Alpna Seth, who spent nearly two decades at Biogen (Nasdaq: BIIB), including the last three years as senior vice presi dent and global head of the biosimilars unit in Switzerland, left the company sometime in July and joined San Francisco-based Vir Biotechnology earlier… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - August 28, 2017 Category: Health Management Authors: Max Stendahl Source Type: news

NJIT Oil spill expert assesses use of deep-sea dispersants in Deepwater Horizon cleanup
(New Jersey Institute of Technology) In a groundbreaking study published today in the Proceedings of the National Academy of Sciences, collaborators from the Woods Hole Oceanographic Institution, New Jersey Institute of Technology, Texas A&M University and the Swiss Federal Institute of Aquatic Science and Technology pooled their scientific and technical expertise to provide some of the first answers to policy questions regarding the use of deep-sea dispersants. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 28, 2017 Category: International Medicine & Public Health Source Type: news

Gender Gap Reduced for Post-AMI In-Hospital Mortality Gender Gap Reduced for Post-AMI In-Hospital Mortality
Women suffering acute MI have experienced great reductions in in-hospital mortality over the past 20 years that have virtually eliminated the gender survival gap, Swiss registry data suggest.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 27, 2017 Category: Consumer Health News Tags: Cardiology News Source Type: news

7 medtech stories we missed this week: Aug. 25, 2017
[Image from unsplash.com]From InspireMD’s Swiss distribution deal to CoreLink’s stackable guide wire launch, here are seven medtech stories we missed this week but thought were still worth a mention. 1. InspireMD announces Swiss distribution deal InspireMD announced in an Aug. 25 press release that it has signed an agreement with 1a Medical to distribute the CGuard EPS (Embolic Prevention System). The new distributor is one of the leading medical distributors in Switzerland and plans to help launch the CGuard there. 2. EarlySense and SleepMed partnered for sleep apnea EarlySense and SleepMed are have forged a p...
Source: Mass Device - August 25, 2017 Category: Medical Devices Authors: Danielle Kirsh Tags: Cosmetic/Aesthetic Diagnostics Food & Drug Administration (FDA) Laboratory Instruments/Laboratory Supplies Research & Development Surgical CoreLink EarlySense InspireMD Life Spine Inc. Medovex MedTech Prollenium SleepMed TechCa Source Type: news

EC approves Novartis ’ breast cancer drug Kisqali
Swiss drugmaker Novartis ’ Kisqali (ribociclib) has received approval from the European Commission (EC) as a first-line treatment for advanced breast cancer. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 24, 2017 Category: Pharmaceuticals Source Type: news

Mudslide in Switzerland Leaves 8 Missing
GENEVA (AP) — Rescue workers used a helicopter and dogs to search for at least eight people still unaccounted for in a Swiss Alpine valley on Thursday, a day after a mudslide and rockslide hit a small village near the Italian border. The village of Bondo, about 130 kilometers (80 miles) north of Milan, has been evacuated. The slide Wednesday morning sent about 4 million cubic meters (140 million cubic feet) of material crashing down, causing an impact equivalent to 3.0 on the Richter scale, senior police official Andrea Mittner said. Police in Graubuenden canton (state) said buildings were damaged, and images from t...
Source: JEMS: Journal of Emergency Medical Services News - August 24, 2017 Category: Emergency Medicine Authors: Associated Press Tags: Major Incidents News Source Type: news

Novartis receives EU approval for breast cancer drug Kisqali
ZURICH (Reuters) - Novartis AG said its drug Kisqali (ribociclib) received European Union approval as first-line treatment for a tough-to-treat breast cancer, bolstering the Swiss drugmaker's bid to challenge U.S. rival Pfizer's Ibrance. (Source: Reuters: Health)
Source: Reuters: Health - August 24, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Roche says FDA grants priority review to hemophilia drug emicizumab
ZURICH (Reuters) - Swiss pharma group Roche said the U.S. Food and Drug Administration (FDA) granted priority review to its emicizumab for hemophilia A with inhibitors. (Source: Reuters: Health)
Source: Reuters: Health - August 24, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

CRISPR Therapeutics, MGH team up on new cancer treatments
CRISPR Therapeutics and Massachusetts General Hospital Cancer Center are teaming up to improve upon new cutting-edge treatments for cancer using gene editing. CRISPR (Nasdaq: CRSP), which is headquartered in Switzerland but conducts research and development in Cambridge, Massachusetts, expects the two-year collaboration to help advance cancer treatments that harness the body’s own immune system. One of the latest trends in biotech is so-called immuno therapies that take certain immune system cells,… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - August 23, 2017 Category: Health Management Authors: Jessica Bartlett Source Type: news

Swiss cheese is a superfood that helps you live longer
A bacteria used in the fermentation of Emmental cheese decreases inflammation and boosts the immune system, say  Seoul researchers. It can also improve signs of ageing. (Source: the Mail online | Health)
Source: the Mail online | Health - August 23, 2017 Category: Consumer Health News Source Type: news

Bacterial infection stresses hematopoietic stem cells
(Kumamoto University) It is becoming clear that immune cells are not the only cells that react to bacterial infection. Researchers from Japan and Switzerland found that bacterial infection also activates hematopoietic stem cells resident in the bone marrow far from the site of infection. This infection significantly reduces the ability of the stem cells to produce blood by forcing them to proliferate. These findings suggest that bacterial infection may lead to a cause of anemia or leukemia. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - August 23, 2017 Category: Infectious Diseases Source Type: news

AC Immune finds new antibodies targeting neurodegenerative diseases
Swiss clinical stage biopharmaceutical company AC Immune has discovered new antibodies against two targets, Alpha-synuclein and TDP-43, in the pathogenesis of neurodegenerative diseases. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 22, 2017 Category: Pharmaceuticals Source Type: news

U.S. Bioservices to resolve kickback claims for $13.4 million: filing
(Reuters) - Specialty pharmacy firm US Bioservices Corp has agreed to pay $13.4 million to settle U.S. government claims that it pushed patients to refill prescriptions of Novartis AG's iron overload drug Exjade in exchange for referrals from the Swiss drugmaker. (Source: Reuters: Health)
Source: Reuters: Health - August 22, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

The Patient Journey: A Tool for Market Access?
What is a patient journey, and why does it matter so much for market access? Should the healthcare profession be focusing more on the patient journey, and what benefit would that have for future sufferers?These are critical questions, especially given that the patient journey is an invaluable tool in: Developing action plans to address issues faced by patients during treatment Rolling out patient support programs Communicating the potential benefits of a given product to increase its value among customers or stakeholders.The ‘patient journey’ is the complete story of a patient's experience in the healthca...
Source: EyeForPharma - August 17, 2017 Category: Pharmaceuticals Authors: Behsad Zomorodi Source Type: news

The Patient Journey: A Tool for Market Access?
What is a patient journey, and why does it matter so much for market access? Should the healthcare profession be focusing more on the patient journey, and what benefit would that have for future sufferers?These are critical questions, especially given that the patient journey is an invaluable tool in: Developing action plans to address issues faced by patients during treatment Rolling out patient support programs Communicating the potential benefits of a given product to increase its value among customers or stakeholders.The ‘patient journey’ is the complete story of a patient's experience in the healthca...
Source: EyeForPharma - August 17, 2017 Category: Pharmaceuticals Authors: Behsad Zomorodi Source Type: news